source
- RA Capital backs Oak Hill Bio's Nasdaq debut via $175 million SPAC mergerRA Capital announced that its SPAC, Research Alliance Corporation III, will merge with Oak Hill Bio, creating a new Nasdaq-listed rare-disease company. The combined entity will start with $175 mil…
- PhRMA pushes back as prescription drug spending continues to rise, according to STAT+ newsletterSTAT+ Health Care Inc. newsletter author Bob Herman reports on the growing concern that prescription drug spending is rising despite industry attempts to downplay it. The piece appears in the July…